Vcare Files Next-Generation TRK Inhibitor in China Homeland

On 4 July, China's National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) accepted the new drug application (NDA) for VC004, a next-generation TRK inhibitor developed by domestic company Vcare PharmaTech. Targeting NTRK fusion-positive solid tumours in adults and adolescents (≥12 years), VC004 is designed for patients with locally advanced/metastatic disease or those who failed prior therapies.

Compared to first-generation TRK inhibitors like Roche's entrectinib (currently the only approved TRK inhibitor in China), VC004 demonstrates superior efficacy and addresses acquired resistance mutations. Phase II trial data showed higher objective response rates (ORR) in both treatment-naive and pretreated patients, with improved safety (lower ≥Grade 3 treatment-related adverse events [TRAEs]). An Investigational New Drug (IND) application has also been approved in the US, positioning VC004 as a potential global leader in its class.

Daily News
AbbVie Reports 2025 Growth Post-Humira as Skyrizi Reaches USD 17.6b
2026-02-06
Henlius Licenses PD-1 mAb Serplulimab to Eisai for Japanese Market
2026-02-06
Lilly Posts Record 2025 Revenue of USD 65.2b, Led by Tirzepatide
2026-02-06
GSK Reports 7% Growth in 2025 Led by Specialty Medicines and Oncology
2026-02-05
Novo's 2025 Revenue Reaches USD 46.9b as Semaglutide Hits USD 34.6b
2026-02-05
Latest Report
Insights into China’s Innovative Drug R&D and Transaction Trends_PharmCube
Details